HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: In a phase I study, 5-azacytidine (a DNMT inhibitor) and romidepsin (a HDAC inhibitor) were combined for the treatment of patients with peripheral T-cell lymphoma (PTCL) (148).